Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/1558
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | de Silva, H.A. | en_US |
dc.contributor.author | Saparamadu, P.A.M. | en_US |
dc.contributor.author | Thabrew, M.I. | en_US |
dc.contributor.author | Pathmeswaran, A. | en_US |
dc.contributor.author | Fonseka, M.M.D. | en_US |
dc.contributor.author | de Silva, H.J. | en_US |
dc.date.accessioned | 2014-10-29T09:21:36Z | - |
dc.date.available | 2014-10-29T09:21:36Z | - |
dc.date.issued | 2003 | en_US |
dc.identifier.citation | Journal of Ethnopharmacology. 2003; 84(1): pp.47-50 | en_US |
dc.identifier.issn | 0378-8741 (Print) | en_US |
dc.identifier.issn | 1872-7573 (Electronic) | en_US |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/1558 | - |
dc.description | Indexed in MEDLINE | - |
dc.description.abstract | Liv.52, a hepatoprotective agent of herbal origin, is used empirically for the treatment of alcoholic liver disease in Sri Lanka. We conducted acontrolled trial to assess the efficacy of Liv.52 in patients with alcoholic liver disease. Patients with evidence of alcoholic liver disease attending outpatient clinics were included in a prospective, double blind, randomized, placebo controlled trial. During the trial period, 80 patients who fulfilled inclusion criteria were randomly assigned Liv.52 (cases; n = 40) or placebo (controls) the recommended dose of three capsules twice daily for 6 months. All patients underwent clinical examination (for which a clinical score was computed), and laboratory investigations for routine blood chemistry and liver function before commencement of therapy (baseline). Thereafter, clinical assessments were done monthly for 6 months, while laboratory investigations were done after 1 and 6 months of therapy. There was no significant difference in the age composition, alcohol intake and baseline liver function between the two groups. The two-sample t-test was used to analyze data obtained after 1 and 6 months of therapy against baseline values. There was no significant difference in clinical outcome and liver chemistry between the two groups at any time point. There were no reports of adverse effects attributable to the drug. Our results suggest that Liv.52 may not be useful in the management of patients with alcohol induced liver disease. | - |
dc.description.abstract | Liv.52, a hepatoprotective agent of herbal origin, is used empirically for the treatment of alcoholic liver disease in Sri Lanka. We conducted a controlled trial to assess the efficacy of Liv.52 in patients with alcoholic liver disease. Patients with evidence of alcoholic liver disease attending outpatient clinics were included in a prospective, double blind, randomized, placebo controlled trial. During the trial period, 80 patients who fulfilled inclusion criteria were randomly assigned Liv.52 (cases; n=40) or placebo (controls) the recommended dose of three capsules twice daily for 6 months. All patients underwent clinical examination (for which a clinical score was computed), and laboratory investigations for routine blood chemistry and liver function before commencement of therapy (baseline). Thereafter, clinical assessments were done monthly for 6 months, while laboratory investigations were done after 1 and 6 months of therapy. There was no significant difference in the age composition, alcohol intake and baseline liver function between the two groups. The two-sample t-test was used to analyze data obtained after 1 and 6 months of therapy against baseline values. There was no significant difference in clinical outcome and liver chemistry between the two groups at any time point. There were no reports of adverse effects attributable to the drug. Our results suggest that Liv.52 may not be useful in the management of patients with alcohol induced liver disease. | en_US |
dc.publisher | Elsevier | en_US |
dc.subject | Liver Diseases | en_US |
dc.subject | Liver Diseases, Alcoholic-drug therapy | en_US |
dc.subject | Plant Extracts-therapeutic use | en_US |
dc.subject | Plants, Medicinal | en_US |
dc.subject | Phytotherapy | en_US |
dc.subject | Randomized Controlled Trial | en_US |
dc.subject | Clinical Trial | en_US |
dc.title | Liv. 52 in alcoholic liver disease: a prospective controlled trial | en_US |
dc.type | Article | en_US |
dc.identifier.department | Pharmacology | en_US |
dc.identifier.department | Biochemistry | en_US |
dc.identifier.department | Medicine | en_US |
dc.identifier.department | Pathology | en_US |
dc.identifier.department | Public Health | en_US |
dc.creator.corporateauthor | International Society for Ethnopharmacology | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.